Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result

We recently published 10 Big Names Beating Wall Street at its Own Game. Celcuity Inc. (NASDAQ:CELC) is one of the best performers on Monday.

Celcuity soared to a fresh record high on Monday, as investors cheered stellar results of the third phase of a clinical trial for the efficacy of gedatolisib in patients with advanced breast cancer.

In intra-day trading, the stock jumped to its highest price of $83, or a 59.7-percent jump, before trimming gains to end the day just up by 35.84 percent at $70.58 apiece.

This followed announcements that its drug candidate—gedatolisib, in combination with two other drugs (called the triplet)—showed a marked 76 percent reduction in the disease progression of enrolled patients with HR+/HER2- advanced breast cancer.

Meanwhile, gedatolisip doublet, which is in combination with a partner drug, reduced the disease progression by 67 percent.

According to Celcuity Inc. (NASDAQ:CELC), hazard ratios for the triplet and doublet were more favorable than have ever been reported by any Phase 3 trial for patients with the said illness.

Following the results, Celcuity Inc. (NASDAQ:CELC) said it is now readying its new drug application with the Food and Drug Administration, with the official submission targeted by the end of the year.

While we acknowledge the potential of CELC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.